Nikalous Tolman, DO
Optometrist · Laramie, WYNPI 1487107280
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.1% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $117, 6.0 times the $19 reported in 2020.
Across 12 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$57
- Bausch & Lomb Americas Inc.$46
- Johnson & Johnson Surgical Vision, Inc.$45
- Coopervision Inc.$33
- Carl Zeiss Meditec AG$19
- Johnson & Johnson Vision Care, Inc.$16
- plus $30 from 2 others
What the payments were for
- Food & beverage$22692%
- Gifts$198%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 2 | $57 |
| Bausch & Lomb Americas Inc. | 2 | $46 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $45 |
| Coopervision Inc. | 1 | $33 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Johnson & Johnson Vision Care, Inc. | 1 | $16 |
| Novartis | 1 | $16 |
| Alcon | 1 | $14 |
How this compares
$246 in reported general payments places this provider in the 60th percentile of 102 optometrist providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CombiganBrimonidine Tartrate/Timolol | 13 | $2,548 |
| Fluorometholone | 20 | $1,162 |
| Latanoprost | 61 | $801 |
| Prednisolone Acetate | 21 | $520 |
| Ketorolac Tromethamine | 28 | $510 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 16 | $427 |
| Brimonidine Tartrate | 12 | $175 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 13 | $152 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Laramie
- Michelle ChaneyLaramie$4K
- Sue LoweLaramie$1K
- Garrett HowellLaramie$469
- Gary PoteetLaramie$213
- Brian PieperLaramie$207
- Mark WellsCheyenne$251K
- David EldredCheyenne$177K
- Joseph MunsellCheyenne$5K
- Jason WhitmanCasper$4K
- Shelby ZemskiCheyenne$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.